Alumis says Phase 3 data show envudeucitinib delivers 54% PASI 100 response at Week 48 in psoriasis trial

Bitget2026/10/09 08:00

Alumis released new Phase 3 psoriasis data presented at the 26th Annual Fall Clinical Dermatology Conference. Envudeucitinib delivered rapid, sustained improvements in hard-to-treat symptoms such as scalp disease, itch, and daily functioning. Patients who switched from placebo or apremilast later in the program reached similar outcomes to those treated continuously. The company remains on track to file a U.S. NDA for moderate-to-severe plaque psoriasis in 4Q 2026. Longer-term follow-up showed a tolerability profile consistent with earlier results, with no new safety issues flagged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090400PRIMZONEFULLFEED9842640) on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37